CompletedPhase 1ACTRN12605000636651
Phase 1 Study of Coxsackievirus A21 for the treatment of melanoma
Intratumoural administration of coxsackievirus A21 for the control of malignant melanoma.
Sponsor
Viralytics Ltd.
Enrollment
3 participants
Start Date
Sep 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Plain Language Summary
Simplified for easier understanding
This early-phase study tests whether Coxsackievirus A21 (a naturally occurring virus) can be used as a treatment for melanoma. It is looking for adults who have been diagnosed with late-stage melanoma. Participants would receive injections of the virus into their tumors and be closely monitored for safety and tumor response.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A single intratumoural injection of coxsackievirus A21.
A single intratumoural injection of coxsackievirus A21.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000636651
Related Trials
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT0696100638 locations
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
NCT069850561 location
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT073716633 locations
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
NCT062067071 location
Modified Vaccine for High Risk or Low Residual Melanoma Patients
NCT018980391 location